Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe study page now returns a 403 Forbidden error, blocking access to the study record and its documents. The visible layout shows a 403 message with header and footer, replacing the expected study content.SummaryDifference18%

- Check10 days agoChange DetectedThe page now includes related topics metadata (Lung cancer and MedlinePlus Genetics) to help users access background information from linked resources.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe NIH grant/contract note was added to the study identifiers, and the page revision was updated to v3.6.6 (replacing v3.6.5).SummaryDifference0.1%

- Check45 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, signaling a minor update to the study record. This does not imply a substantive change to the study details.SummaryDifference0.0%

- Check52 days agoChange DetectedLung cancer and the related topics section, including MedlinePlus Genetics, were removed from the page content. This changes the list of linked topics shown but does not alter the study's design, endpoints, or enrollment information.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page now lists Lung cancer and related topics, and adds a MedlinePlus Genetics reference. The revision tag was updated from v3.6.3 to v3.6.4.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.